The David H. Koch Institute for Integrative Cancer Research at MITThe David H. Koch Institute for Integrative Cancer Research at MIT

Massachusetts Institute of Technology

National Cancer Institute Cancer Center

Science + Engineering... Conquering Cancer Together

Summer Symposium 2021

Engineering the Next Wave of Immunotherapy
Friday, September 17, 2021
8:30 a.m. EDT on Zoom

The 19th Annual Koch Institute Summer Symposium will be held virtually on September 17, 2021 and will focus on cancer immunotherapy. Register now. Please note that this year's presenter sessions will NOT be recorded.

Cancer immunotherapy has revolutionized the landscape of cancer treatment, our thinking of tumor biology and clinical practice. Following the groundbreaking successes of checkpoint blockade therapy and CAR T cell therapy, culminating in multiple FDA-approved treatments and the awarding of the 2018 Nobel Prize in Medicine to Jim Allison and Tasuku Honjo, the field is currently at a critical juncture.  

While checkpoint blockade therapy has demonstrated that the immune system can be harnessed to fight cancer, the next generation of treatments will require us to understand what causes resistance in non-responders, how this can be overcome, and how these issues are best addressed clinically. Discussing these questions will be at the core of this symposium as we move towards our ultimate goal to increase the number of patients benefiting from immunotherapy

8:30 a.m.
Presentations


8:30 a.m. - Welcome & Introduction

8:45 a.m. - Targeting T Cells 
Rafi Ahmed (T Cell Lifestyle in Chronic Infection and Cancer: Implications for Immunotherapy)
Chris Love (Single-Cell Clonotypic Analysis of T cells)
Michael Dougan (In vivo blockade of immune regulator receptors in humans: immunotherapy toxicities)

10:30 a.m. - Thinking Beyond T Cells
Lauren Zasadil (Immune Clearance of Aneuploid Cells in vivo)
Yasmine Belkaid (Endogenous retroviruses control of responses to the microbiota)
Stefani Spranger (Engaging the dendritic cell compartment to induce potent anti-tumor T cell responses)
Juan Mendoza (Enhancing the therapeutic potential of interferons through molecular engineering)

1:30 p.m. - Engineering Clinical Translation  
Chris Garcia (Opening new immunotherapeutic doors at the cell surface through receptor-ligand engineering)
Juliana Idoyaga (Emerging dendritic cell heterogeneity: the in-betweens)
Crystal Mackall (Next Generation CAR T cells to Overcome Resistance)

3:15 p.m.
Panel Discussion: Clinical Translation: A Real Life Perspective


Daniel Chen, Michael Dougan, Kimberly Shafer-Weaver
Moderators: Steven Silverstein, Jane Wilkinson

Thank You to Our Sponsors


Agilent Technologies, Inc.
Dragonfly Therapeutics, Inc.
Repertoire Immune Medicines
Ribon Therapeutics
Skyhawk Therapeutics